UPDATE: RBC Capital Starts Gemphire Therapeutics (GEMP) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/19/2024
- Nasdaq, S&P tumble as Netflix, chip stocks drag; AmEx boosts Dow
- Sony/Apollo bid for Paramount could be worth as much as $29 billion - Source
- Netflix Q1 earnings top estimates on blowout subscriber growth
- Nasdaq tumbles, Treasuries dip amid earnings, geopolitical crosscurrents
- Gold prices rally past $2,400 on reports of Israel strikes on Iran
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- Jabil falls after placing CEO on paid leave amid internal investigation
- Frontier Communications (FYBR) says third party had gained unauthorized access to portions of its information technology environment
- Ibotta (IBTA) Prices 6.56M Share IPO at $88/sh
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
Jefferies Starts Gemphire Therapeutics (GEMP) at Buy
August 30, 2016 6:54 AM EDTJefferies initiates coverage on Gemphire Therapeutics (NASDAQ: GEMP) with a Buy rating and a price target of $15.00.
Analyst Matthew Andrews commented, "Initiating with a Buy Rating and $15 price target. Gemcabene is being developed to address the large, evolving global dyslipidemia... More
Canaccord Genuity Starts Gemphire Therapeutics (GEMP) at Buy
August 30, 2016 6:40 AM EDTCanaccord Genuity initiated coverage on Gemphire Therapeutics (NASDAQ: GEMP) with a Buy rating and a price target of $17.00.
For an analyst ratings summary and ratings history on Gemphire Therapeutics click here. For more ratings news on Gemphire Therapeutics click here.
Shares of Gemphire Therapeutics closed at $10.15 yesterday.
... More
